Literature DB >> 10680784

Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study.

N Attal1, V Gaudé, L Brasseur, M Dupuy, F Guirimand, F Parker, D Bouhassira.   

Abstract

OBJECTIVE: To investigate the effects of systemic administration of lidocaine on different components of neuropathic central pains by quantitative sensory testing.
METHODS: The efficacy of systemic lidocaine (5 mg/kg IV over 30 minutes) was evaluated in a double-blind, placebo-controlled, and cross-over fashion, on both spontaneous ongoing pain and evoked pains (allodynia and hyperalgesia) in 16 patients with chronic poststroke (n = 6) or spinal cord injury (n = 10) related pain.
RESULTS: Lidocaine was significantly superior to the placebo (saline) in reducing the intensity of spontaneous ongoing pain for up to 45 minutes after the injection: 10 of 16 patients (62.5%) receiving lidocaine showed a significant reduction in spontaneous pain, whereas only six patients showed this after the placebo. Lidocaine also significantly reduced the intensity of brush-induced allodynia and mechanical hyperalgesia, but was no better than the placebo against thermal allodynia and hyperalgesia. In general, the side effects were moderate and consisted mainly of lightheadedness (44%).
CONCLUSIONS: Systemic lidocaine can induce a significant and selective reduction of several components of pain caused by CNS injuries. The observed preferential antihyperalgesic and antiallodynic effects of this drug suggest a selective central action on the mechanisms underlying these evoked pains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10680784     DOI: 10.1212/wnl.54.3.564

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

Review 1.  Pharmacological management of neuropathic pain.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals.

Authors: 
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Neural response to lidocaine in healthy subjects.

Authors:  Bryon Adinoff; Michael D Devous; Donald C Cooper; Susan E Best; Thomas S Harris; Mark J Williams
Journal:  Psychiatry Res       Date:  2009-06-28       Impact factor: 3.222

5.  Treatment of Neuropathic Pain.

Authors:  Matthew T Mendlik; Tanya J Uritsky
Journal:  Curr Treat Options Neurol       Date:  2015-12       Impact factor: 3.598

Review 6.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

Review 7.  Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy.

Authors:  Ian Carroll
Journal:  Curr Pain Headache Rep       Date:  2007-02

8.  Lidocaine infusion as a rescue analgesic in the perioperative setting.

Authors:  C Clarke; I McConachie; R Banner
Journal:  Pain Res Manag       Date:  2008 Sep-Oct       Impact factor: 3.037

Review 9.  Neuromodulating drugs for the symptomatic treatment of neuropathic pain.

Authors:  Miroslav Backonja
Journal:  Curr Pain Headache Rep       Date:  2004-06

10.  Lack of impact of intravenous lidocaine on analgesia, functional recovery, and nociceptive pain threshold after total hip arthroplasty.

Authors:  Frédéric Martin; Kamel Cherif; Marc Emile Gentili; Dominique Enel; Emuri Abe; Jean Claude Alvarez; Jean Xavier Mazoit; Marcel Chauvin; Didier Bouhassira; Dominique Fletcher
Journal:  Anesthesiology       Date:  2008-07       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.